Rapamycin administration is not a valid therapeutic strategy for every case of mitochondrial disease

BACKGROUND: The vast majority of mitochondrial disorders have limited the clinical management to palliative care. Rapamycin has emerged as a potential therapeutic drug for mitochondrial diseases since it has shown therapeutic benefits in a few mouse models of mitochondrial disorders. However, the un...

Descripción completa

Detalles Bibliográficos
Autores principales: Barriocanal-Casado, Eliana, Hidalgo-Gutiérrez, Agustín, Raimundo, Nuno, González-García, Pilar, Acuña-Castroviejo, Darío, Escames, Germaine, López, Luis C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492073/
https://www.ncbi.nlm.nih.gov/pubmed/30898651
http://dx.doi.org/10.1016/j.ebiom.2019.03.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492073/
https://www.ncbi.nlm.nih.gov/pubmed/30898651
http://dx.doi.org/10.1016/j.ebiom.2019.03.025

Ejemplares similares